We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Announces Clinical Milestone in Blood Disorders Program
News

MorphoSys Announces Clinical Milestone in Blood Disorders Program

MorphoSys Announces Clinical Milestone in Blood Disorders Program
News

MorphoSys Announces Clinical Milestone in Blood Disorders Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Clinical Milestone in Blood Disorders Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that it has received a milestone payment from Novartis in connection with the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of blood disorders.

This becomes the eleventh therapeutic antibody made using MorphoSys's technologies that Novartis is evaluating in clinical trials. The associated milestone payment was booked in Q2 2015.

"With eleven therapeutic antibody programs in clinical development to date, our alliance with Novartis has resulted in a substantial drug candidate portfolio," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news represents the second clinical milestone with our partners during the course of this year."

MorphoSys's collaboration with Novartis has resulted in eleven clinical programs to date, six of which are in Phase 1 development, with another four programs in Phase 2 and one in Phase 3.

In total, MorphoSys's proprietary and partnered clinical pipeline currently comprises 24 unique antibody molecules, which are being evaluated in more than 50 clinical trials.

Advertisement